Biotech | September 22, 2022
Charsire's new drug aims to capture dementia treatment market
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala
The capital expansion program commenced in June 2022 and is expected to complete in 2024
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
Meclizine Hydrochloride Tablets had estimated annual sales of USD 29 million in the U.S.
The product will be manufactured at Lupin’s facility in Goa, India.
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.
Subscribe To Our Newsletter & Stay Updated
